关注
Taiki Hakozaki
Taiki Hakozaki
Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
在 cick.jp 的电子邮件经过验证
标题
引用次数
引用次数
年份
The gut microbiome associates with immune checkpoint inhibition outcomes in patients with advanced non–small cell lung cancer
T Hakozaki, C Richard, A Elkrief, Y Hosomi, M Benlaïfaoui, I Mimpen, ...
Cancer Immunology Research 8 (10), 1243-1250, 2020
2012020
Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer
T Hakozaki, Y Okuma, M Omori, Y Hosomi
Oncology Letters 17 (3), 2946-2952, 2019
1182019
Switching administration of anti‐PD‐1 and anti‐PD‐L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non‐small cell lung cancer: case series …
S Kitagawa, T Hakozaki, R Kitadai, Y Hosomi
Thoracic Cancer 11 (7), 1927-1933, 2020
642020
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non–small cell lung cancer: A real …
A Desilets, F Blanc-Durand, S Lau, T Hakozaki, R Kitadai, J Malo, ...
European Journal of Cancer 142, 83-91, 2021
612021
Statins improve survival in patients previously treated with nivolumab for advanced non‑small cell lung cancer: An observational study
M Omori, Y Okuma, T Hakozaki, Y Hosomi
Molecular and clinical oncology 10 (1), 137-143, 2019
602019
The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases
R Kitadai, Y Okuma, T Hakozaki, Y Hosomi
Journal of Cancer Research and Clinical Oncology 146, 777-785, 2020
482020
A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of nonresponse to immune checkpoint inhibitors
FY Shaikh, JR White, JJ Gills, T Hakozaki, C Richard, B Routy, Y Okuma, ...
Clinical Cancer Research 27 (9), 2571-2583, 2021
352021
Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy
T Hakozaki, Y Hosomi, A Shimizu, R Kitadai, K Mirokuji, Y Okuma
Journal of Cancer Research and Clinical Oncology 146, 2659-2668, 2020
292020
The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non–Small Cell Lung Cancer. Cancer Immunol. Res. 2020; 8: 1243–1250. doi: 10 …
T Hakozaki, C Richard, A Elkrief, Y Hosomi, M Benlaïfaoui, I Mimpen, ...
CIR-20-0196.[Abstract][CrossRef][Google Scholar], 0
29
Cancer cachexia among patients with advanced non-small-cell lung cancer on immunotherapy: an observational study with exploratory gut microbiota analysis
T Hakozaki, A Nolin-Lapalme, M Kogawa, Y Okuma, S Nakamura, ...
Cancers 14 (21), 5405, 2022
222022
Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
J Feng, Y Li, B Wei, L Guo, W Li, Q Xia, C Zhao, J Zheng, J Zhao, R Sun, ...
Translational Lung Cancer Research 11 (4), 617, 2022
202022
Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report
T Hakozaki, Y Okuma, J Kashima
BMC cancer 18, 1-4, 2018
202018
Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer
T Hakozaki, Y Hosomi, R Kitadai, S Kitagawa, Y Okuma
Journal of Cancer Research and Clinical Oncology 146, 2957-2966, 2020
182020
Polypharmacy among older advanced lung cancer patients taking EGFR tyrosine kinase inhibitors
T Hakozaki, T Matsuo, A Shimizu, Y Ishihara, Y Hosomi
Journal of Geriatric Oncology 12 (1), 64-71, 2021
172021
A multicenter, randomized phase III study comparing platinum combination chemotherapy plus pembrolizumab with platinum combination chemotherapy plus nivolumab and ipilimumab …
Y Shiraishi, T Hakozaki, S Nomura, T Kataoka, K Tanaka, S Miura, ...
Clinical Lung Cancer 23 (4), e285-e288, 2022
162022
Efficacy of first‐line immune checkpoint inhibitors in patients with advanced NSCLC with KRAS, MET, FGFR, RET, BRAF, and HER2 alterations
Y Uehara, K Watanabe, T Hakozaki, M Yomota, Y Hosomi
Thoracic Cancer 13 (11), 1703-1711, 2022
112022
Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in …
Y Uehara, T Hakozaki, R Kitadai, K Narita, K Watanabe, K Hashimoto, ...
Translational Lung Cancer Research 11 (2), 135, 2022
102022
Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study
D Zhang, Y Shi, X Liu, J Liu, Y Xu, J Zhao, W Zhong, L Käsmann, ...
Translational Lung Cancer Research 11 (7), 1420, 2022
92022
Combined small and squamous transformation in EGFR-mutated lung adenocarcinoma
T Hakozaki, M Kitazono, M Takamori, T Kiriu
Internal Medicine 59 (10), 1291-1294, 2020
92020
Senescence marker protein 30 inhibits tumor growth by reducing HDAC4 expression in non-small cell lung cancer
C Shao, K Guo, L Xu, Y Zhang, H Duan, Y Feng, M Pan, D Lu, X Ren, ...
Translational Lung Cancer Research 10 (12), 4558, 2021
72021
系统目前无法执行此操作,请稍后再试。
文章 1–20